WARNING LETTER · 06 NOV 2026FEI 3009867894 · Pilar, Buenos Aires

Umicore Argentina: 300 failed lab results at a cancer-API plant

FDA says the Pilar plant invalidated more than 200 out-of-spec results since 2021 and blamed its analysts. Umicore Argentina holds US files for cisplatin, carboplatin, oxaliplatin and arsenic trioxide.

Is your product on this list?

Products at risk. Who's in.

DMF on fileAPI, supply not confirmed
MOLECULE FORM SOLD IN THE US BY LINK TO SITE RISK WHO'S IN Action
Arsenic trioxide API Not disclosed by FDA DMF ON FILE WARNING LETTER 5 API (5 US DMF) See who's in
Cisplatin API Not disclosed by FDA DMF ON FILE WARNING LETTER 24 API (12 US DMF) See who's in
Carboplatin API Not disclosed by FDA DMF ON FILE WARNING LETTER 22 API (17 US DMF) See who's in
Oxaliplatin API Not disclosed by FDA DMF ON FILE WARNING LETTER 29 API (21 US DMF) See who's in

FDA often redacts product names in its letters. Rows marked "FDA label" come from openFDA drug labels that name this site. "Who's in" counts manufacturers of the same molecule in the API-FDF database; names and contacts are inside.

What FDA found
  1. Over 300 out-of-spec results since 2021 for assay, impurities, microbiology and water. More than 200 were invalidated.
  2. When the lab found no error, the plant still blamed analysts and retrained them instead of opening a manufacturing investigation.
  3. No identification of microbes in failed API and water samples, a gap FDA already cited in 2018.
  4. Investigators saw peeling material inside a tank, residues in tanks logged as clean, stagnant water in a transfer line and live insects near API packaging.
Timeline

How it got here

4–9 JUN 2026 FDA inspects the Pilar plant
30 JUN 2026 Umicore answers the Form 483
6 NOV 2026 Warning Letter: response called inadequate
NEXT FDA may refuse imports and hold applications that name the site

Umicore Argentina is under a warning letter. 5 arsenic trioxide API makers are in.

Open the list on API-FDF